Skip to content
Screener

Exelixis EXEL Acquired in-process research and development

Acquired in-process research and development at other companies

Eli Lilly logo
Eli LillyLLY
$2.78B+1,703%
Immunome logo
ImmunomeIMNM
$9.01M+44.3%
CTO
Citius Oncology, Inc.CTOR
$40M+2,393%
Gilead Sciences logo
Gilead SciencesGILD
$539M—

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$12.93B+27.4%
Enterprise value$12.82B+26.1%
P/E15×-1.8×
P/S5.3×+0.8×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Depreciation and amortization13,93214,687
Stock-based compensation61,61362,001
Non-cash lease expense11,92112,166
Acquired in-process research and development technology10,600750
Other, net(3,295)(10,617)
Changes in operating assets and liabilities:
Trade receivables, net(35,297)(26,837)
Inventory(3,433)2,568

Item 1. Financial Statements.

FAQ

What is Exelixis's acquired in-process research and development?
Exelixis (EXEL) reported acquired in-process research and development of $8.58M in Q2 2026.
How has Exelixis's acquired in-process research and development changed year-over-year?
Exelixis's acquired in-process research and development increased by 1043.3% year-over-year, from $750K to $8.58M.
What is the long-term trend for Exelixis's acquired in-process research and development?
Over 4 years (2021 to 2025), Exelixis's acquired in-process research and development has grown at a -3.8% compound annual growth rate (CAGR), from $14M to $12M.
What does acquired in-process research and development mean?
Acquired in-process research and development (IPR&D) represents the cash paid to acquire rights to drug candidates or technologies that have not yet reached regulatory approval. In the biotech industry, this is a critical indicator of external innovation and pipeline expansion. It is classified as an investing activity because it represents a capital allocation toward future growth.

Ask your AI about Exelixis's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude